HIV's genome of RNA includes the code for reverse transcriptase (RT), an enzyme that acts early in infection to synthesize a DNA genome off of an RNA template. The HIV genome also codes for protease (PR), an enzyme that acts later in infection by cutting long viral polyproteins into smaller, functional proteins. Both RT and PR represent potential targets for antiretroviral drugs. Drugs called nucleoside analogs (NA) act against RT, whereas drugs called protease inhibitors (PI) act against PR. Which of the following treatment options would most likely avoid the evolution of drug-resistant HIV (assuming no drug interactions or side effects)?
(a) Use a series of NAs, one at a time, and change about once a week.
(b) Use a single PI, but slowly increase the dosage over the course of a week.
(c) Use high doses of NA and a PI at the same time for a period not to exceed one day.
(d) Use moderate doses of NA and two different PIs at the same time for several months.
